| 3 Months | 12 Months | 24 Months | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | Total | WFNS I-III | WFNS IV + V | p-value | Total | WFNS I-III | WFNS IV + V | p-value | Total | WFNS I-III | WFNS IV + V | p-value |
GOSE ≥5 | 56.5% (26/46) | 77.8% (21/27) | 26.3% (5/19) | 0.002 | 57.1% (20/35) | 73.7% (14/19) | 37.5% (6/16) | 0.07 | 74.1% (20/27) | 81.3% (13/16) | 63.6% (7/11) | 0.39 |
mRS ≤3 | 69.6% (32/46) | 85.2% (23/27) | 47.4% (9/19) | 0.016 | 68.6% (24/35) | 78.9% (15/19) | 56.3% (9/16) | 0.28 | 77.8% (21/27) | 87.5% (14/16) | 63.6% (7/11) | 0.19 |
NAB-S impossible | 35.1% (13/37) | 23.8% (5/21) | 50.0% (8/16) | 0.19 | 24.1% (7/29) | 15.4% (2/13) | 31.3% (5/16) | 0.41 | 11.1% (3/27) | 6.3% (1/16) | 18.2% (2/11) | 0.55 |
Impaired MoCA | 68.6% (24/35) | 60.0% (12/20) | 80.0% (12/15) | 0.28 | 66.7% (18/27) | 50.0% (6/12) | 80.0% (12/15) | 0.13 | 58.3% (14/24) | 64.3% (9/14) | 50.0% (5/10) | 0.68 |
Returned to work | 0% (0/42) | 0% (0/23) | 0% (0/19) | 1.0 | 23.5% (8/34) | 36.8% (7/19) | 6.7% (1/15) | 0.05 | 37.5% (9/24) | 53.8% (7/13) | 18.2% (2/11) | 0.11 |